1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Hidradenitis Suppurativa - Pipeline Review, H1 2016

Hidradenitis Suppurativa - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 46 pages

Hidradenitis Suppurativa - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Hidradenitis Suppurativa - Pipeline Review, H1 2016’, provides an overview of the Hidradenitis Suppurativa pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hidradenitis Suppurativa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hidradenitis Suppurativa and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hidradenitis Suppurativa
- The report reviews pipeline therapeutics for Hidradenitis Suppurativa by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hidradenitis Suppurativa therapeutics and enlists all their major and minor projects
- The report assesses Hidradenitis Suppurativa therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hidradenitis Suppurativa

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hidradenitis Suppurativa
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hidradenitis Suppurativa pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Hidradenitis Suppurativa - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hidradenitis Suppurativa Overview 6
Therapeutics Development 7
Pipeline Products for Hidradenitis Suppurativa - Overview 7
Hidradenitis Suppurativa - Therapeutics under Development by Companies 8
Hidradenitis Suppurativa - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Hidradenitis Suppurativa - Products under Development by Companies 11
Hidradenitis Suppurativa - Companies Involved in Therapeutics Development 12
Cellceutix Corporation 12
Celtaxsys, Inc. 13
Delenex Therapeutics AG 14
Johnson and Johnson 15
Novartis AG 16
Hidradenitis Suppurativa - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
acebilustat - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
adalimumab biosimilar - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
CJM-112 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
DLX-105 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
DLX-2751 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Small Molecule to Disrupt Cell Membrane for Hidradenitis Suppurativa - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
ustekinumab - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Hidradenitis Suppurativa - Recent Pipeline Updates 37
Hidradenitis Suppurativa - Dormant Projects 42
Hidradenitis Suppurativa - Discontinued Products 43
Hidradenitis Suppurativa - Product Development Milestones 44
Featured News and Press Releases 44
Sep 11, 2014: Delenex Announces New Clinical Data 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 45
Disclaimer 46

List of Tables
Number of Products under Development for Hidradenitis Suppurativa, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Clinical Stage Development, H1 2016 9
Comparative Analysis by Early Stage Development, H1 2016 10
Products under Development by Companies, H1 2016 11
Hidradenitis Suppurativa - Pipeline by Cellceutix Corporation, H1 2016 12
Hidradenitis Suppurativa - Pipeline by Celtaxsys, Inc., H1 2016 13
Hidradenitis Suppurativa - Pipeline by Delenex Therapeutics AG, H1 2016 14
Hidradenitis Suppurativa - Pipeline by Johnson and Johnson, H1 2016 15
Hidradenitis Suppurativa - Pipeline by Novartis AG, H1 2016 16
Assessment by Monotherapy Products, H1 2016 17
Number of Products by Stage and Target, H1 2016 19
Number of Products by Stage and Mechanism of Action, H1 2016 21
Number of Products by Stage and Route of Administration, H1 2016 23
Number of Products by Stage and Molecule Type, H1 2016 25
Hidradenitis Suppurativa Therapeutics - Recent Pipeline Updates, H1 2016 37
Hidradenitis Suppurativa - Dormant Projects, H1 2016 42
Hidradenitis Suppurativa - Discontinued Products, H1 2016 43

List of Figures
Number of Products under Development for Hidradenitis Suppurativa, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Clinical Stage Development, H1 2016 9
Assessment by Monotherapy Products, H1 2016 17
Number of Products by Targets, H1 2016 18
Number of Products by Stage and Targets, H1 2016 18
Number of Products by Mechanism of Actions, H1 2016 20
Number of Products by Stage and Mechanism of Actions, H1 2016 20
Number of Products by Routes of Administration, H1 2016 22
Number of Products by Stage and Routes of Administration, H1 2016 22
Number of Products by Molecule Types, H1 2016 24
Number of Products by Stage and Molecule Types, H1 2016 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Nuclear Factor Erythroid 2 Related ...

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen ...

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016’, ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.